![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Organon |
Information provided by: | Organon |
ClinicalTrials.gov Identifier: | NCT00552929 |
The objective of the trial was to establish the dose-response relation of Org 25969 given as a reversal agent of rocuronium or vecuronium at 1-2 PTC during sevoflurane anesthesia for Caucasian subjects
Condition | Intervention | Phase |
Anesthesia, General |
Drug: Sugammadex Drug: Placebo |
Phase II |
Genetics Home Reference related topics: | ataxia-telangiectasia |
MedlinePlus related topics: | Anesthesia Ataxia Telangiectasia |
ChemIDplus related topics: | Rocuronium ORG 9426 Sugammadex Vecuronium bromide |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind (Outcomes Assessor), Dose Comparison, Parallel Assignment, Efficacy Study |
Official Title: | A Multi -Center, Randomized, Open -Label, Prospective Bridging, Parallel Dose-Finding Trial Comparing Efficacy, Safety and Pharmacokinetics of 4 Doses of Org 25969 and Placebo Administered at 1-2 PTC After Rocuronium or Vecuronium in Japanese and Caucasian Subjects. Part B: Caucasian Subjects. |
Enrollment: | 100 |
Study Start Date: | October 2005 |
Study Completion Date: | September 2006 |
Primary Completion Date: | September 2006 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
1: Experimental
Sugammadex
|
Drug: Sugammadex
4 Doses of Sugammadex Administered at 1-2 PTC After 0.9 mg/kg Rocuronium or 0.1 mg/kg Vecuronium
|
2: Placebo Comparator
Placebo
|
Drug: Placebo
4 Doses of placebo Administered at 1-2 PTC After Rocuronium or Vecuronium
|
Ages Eligible for Study: | 20 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion criteria:
Responsible Party: | NV Organon, part of Schering-Plough Corporation ( Study Director ) |
Study ID Numbers: | 19.4.209B |
First Received: | October 31, 2007 |
Last Updated: | August 15, 2008 |
ClinicalTrials.gov Identifier: | NCT00552929 |
Health Authority: | Belgium: Directoraat-Generaal Geneesmiddelen |
|
![]() |